Twitter | Search | |
Search Refresh
Manuel Martin Nov 14
Any price that limits access is unethical because limiting access -> people die. When the increased revenues are used for share buybacks, dividends and higher exec compensation someone is making the decision that profits matter more than lives.
Reply Retweet Like
Jill D McArdle 🚀 Nov 14
Chantal Bélorgey of Haute Autorité de Santé France says "all that is new is not innovative" 👏👏👏 "Low evidence and high prices is becoming the norm". We need to "see better and pay better" 👏👏👏
Reply Retweet Like
Lorenzo De Santis Nov 14
If even , one of the richest countries in the 🌎, is concerned about prices, you know we need a . Bjorn Larsen speaking about how to deal with unsustainable high-prices and .
Reply Retweet Like
European Ombudsman Nov 14
"We await judgement following the recent opinion of Advocate General Hogan, and hope the great progress made in this area over many years is not undermined." - 📌 📌
Reply Retweet Like
Manuel Martin Nov 14
Norway is the 3rd richest country in the world. If they have a pricing problem then everyone has a pricing problem..
Reply Retweet Like
Lorenzo De Santis Nov 14
45% of see their treatment delayed by med . How to prevent? Suggestions from : 1)Be about causes 2)Have mandatory 3)Enforce obligations throughout the supply chain, including w/
Reply Retweet Like
European Ombudsman Nov 14
"Our work has led to several changes in the and accountability of , which increases trust in the agency, and has real benefits for patients." - ✔️
Reply Retweet Like
Anna Prokůpková Nov 14
The thing with -based is that needs to be ready to lose money if their meds don't deliver expected outcomes...So far it seems the value discussion has only been to increase the price when the drug happens to work...🤔
Reply Retweet Like
Dimitri Eynikel Nov 14
. making the case that some medicines are the results of collective efforts, public and private. Transparency can and should help acknowledge these efforts.
Reply Retweet Like
Viviana Galli Nov 14
Following the value-based price philosophy, how much would electricity or education cost? Audun Hågå of points out
Reply Retweet Like
Boris Azais Nov 14
most transparent industrial sector: 1️⃣Pipeline is visible years ahead; 2️⃣ Clinical trials & results are published; 3️⃣ Patents are public; 4️⃣ Revenues and accounts are published every quarter. Which other sector provides so much information?
Reply Retweet Like
Marcel van Raaij Nov 14
Participating in the EPHA meeting on access and affordable medicines today.
Reply Retweet Like
Alex Filicevas Nov 14
This morning challenging the status quo on medicines policy at Universal Access and Afdordable Medicines Forum
Reply Retweet Like
Charlotte Roffiaen Nov 14
Chantal Bélorgey from supports not only on price of but on everything. She added that patients' voice need to be listenedd too. Let's work together to make it happen
Reply Retweet Like
Jillian Deutsch Nov 14
There’s a shortage of 4 essential cancer drugs in Romania right now. “That’s a scandal,” said.
Reply Retweet Like
EONS Nov 14
HTA bodies need to ensure cost-effectiveness in . is a relevant issue. "Unethical high on some new medicines" quotes the Norwegian Minister Health Mr. Bent Høei.
Reply Retweet Like
European Ombudsman Nov 14
"We have promoted transparency and good practices at , for example on access to clinical study reports and pre-submission meetings" - , European Ombudsman's office, speaking at forum. 📌 📌
Reply Retweet Like
Anne-Pierre Pickaert Nov 14
. ⁦⁩ Fergal O’Regan on transparency: it is a means to generate trust in the system, i.e. and industry.
Reply Retweet Like
Charlotte Roffiaen Nov 14
. reminds that is key in democratic governments + secrecy is hardly ever in the public interest. MoHs negotiate on behalf of citizens
Reply Retweet Like
European Cancer Leagues Nov 14
💊 Chair of Task Force speaks today to a full house at about the role of in plan!
Reply Retweet Like